Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2026)

Bioventus (BVS) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $673.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 4.73% year-over-year to $673.3 million; the trailing twelve-month figure through Jun 2026 stood at $2.7 billion (down 6.44% YoY), and the FY2025 full-year result was $683.6 million, down 6.1% from the prior year.
• Liabilities and Shareholders Equity grew to $673.3 million in Q2 2026 per BVS's latest filing, from $650.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2022 and bottomed at $650.5 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $873.0 million across 5 years, with a median of $793.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 113.51% in 2022, then plunged 41.98% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then slumped by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 6.1% to $683.6 million in 2025, then fell by 1.49% to $673.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $673.3 million, $650.5 million, and $683.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.